Anatomage Inc. Names Recipients of the 2025 Anatomage Teacher Awards
This year's awards highlight four distinct categories, each celebrating a unique facet of educational excellence. After a thorough nomination and review process, a panel of expert judges selected the following teachers as this year's honorees:
Outstanding Teacher AwardRecognizing one teacher who has made a significant impact on their students, school, and community through exemplary classroom science learning, inspiring STEM engagement and demonstrating innovative Anatomage integration.Winner: Mikaela Drake, Ph.D., Associate Professor of Health Sciences and Assistant Program Director, Butler University
Trailblazer AwardHonoring a teacher who utilizes Anatomage technology in a unique and groundbreaking way to enhance learning and motivate students.Winner: Joel Otte, EMS and Fire Science Education Coordinator, Des Moines Area Community College
Top Contributor AwardAwarded to the educator whose high-quality contributions on the content-sharing platform Anatomage Share stands out for its educational value, clarity, and positive influence on the broader teaching community.Winner: Katelyn Christensen, Anatomy & Physiology Teacher, Grand Terrace High School
Research Pioneer AwardRecognizing an educator who is leveraging Anatomage in published studies or active academic research, contributing meaningfully to the advancement of education, medicine, and science.Winner: Erica Ausel, Ph.D., Assistant Professor of Anatomy, Marian University
Each of these educators has demonstrated exceptional commitment to student learning, incorporating Anatomage's advanced visualization products to create immersive and transformative educational experiences. To be considered for an award, nominees were invited to share how they use Anatomage in their lessons, provide examples of impactful content or research, and reflect on how technology supports their teaching goals in a digital-first world.
"We are proud to recognize these exceptional educators who are shaping the future of medical and science education," said Jack Choi, CEO of Anatomage. "Through their innovative use of Anatomage technology, they have elevated student engagement, enhanced learning outcomes, and brought science to life in meaningful ways. We congratulate them on these well-deserved honors."
Each winner will receive a $1,000 cash prize, a commemorative trophy and certificate recognizing their achievement, as well as a complimentary pass to the 2025 Anatomage Conference, where leading educators and healthcare professionals gather to share ideas and shape the future of healthcare and science education.
The Anatomage Teacher Awards reflect Anatomage's ongoing mission to support educators with the tools, recognition, and platform they need to advance anatomical education and research on a global scale. By celebrating the achievements of outstanding educators, Anatomage reaffirms its commitment to inspiring the next generation of science and healthcare leaders.
About Anatomage
Anatomage is a market leader in medical imaging and education technology, transforming traditional learning through continuous innovation. With an ecosystem of medical imaging software and hardware, the company delivers world-class anatomy and physiology content at the highest level of accuracy. Anatomage is committed to enhancing its technologies to transform standard anatomy learning, medical diagnosis, treatment planning, as well as revolutionize science education.
Media Contact:Dr. Jack ChoiCEO, Anatomage Inc.Phone: 1-408-885-1474Email: info@anatomage.comwww.anatomage.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/anatomage-inc-names-recipients-of-the-2025-anatomage-teacher-awards-302494815.html
SOURCE Anatomage Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 hours ago
- Yahoo
Myosin Therapeutics Awarded $4.5 Million NCI Bridge Grant to Advance Phase I Trial of MT-125 in Glioblastoma
JUPITER, Fla., Aug. 19, 2025 /PRNewswire/ -- Myosin Therapeutics, a biotechnology company developing novel therapies for aggressive cancers, today announced it has been awarded a $4.5M Phase IIB Bridge Award from the National Cancer Institute's (NCI) Small Business Innovation Research (SBIR) program. The funding will support Myosin Therapeutic's Phase I STAR-GBM dose escalation and expansion trial of MT-125, a first-in-class novel small molecule therapeutic being evaluated in patients with newly diagnosed, MGMT unmethylated glioblastoma. Glioblastoma remains among the most lethal cancers, with median survival measured in months. MT-125 targets non-muscle myosin II, a critical driver of tumor cell invasion, proliferation and treatment resistance, representing a novel therapeutic approach that is distinct from existing standards of care. The STAR-GBM trial will assess the safety, tolerability, and pharmacokinetics of MT-125 in this patient population with significant unmet need. Exploratory endpoints include measures of efficacy, including progression-free survival and overall survival. The NCI SBIR program is one of the most competitive federal funding mechanisms for cancer-focused innovation, providing support to small businesses with technologies that have strong scientific merit, commercial potential, and a clear path to clinical impact. Bridge Awards, which require that matching funds from private capital be raised first, are reserved for companies with promising, later-stage projects that have already demonstrated significant technical progress and the potential to attract substantial private investment. "The NCI Bridge Award was perfectly timed to support our STAR-GBM trial, for which patient enrollment is set to begin in November," said Dr. Courtney Miller, co-founder and CEO of Myosin Therapeutics. "It will enable us to generate the data needed to position the program for later-stage development, potential partnerships, and future expansion into a wider range of patients. Our ultimate goal is to deliver a transformative treatment option for patients who currently face limited or inadequate therapeutic choices." About Myosin TherapeuticsMyosin Therapeutics is a Jupiter, FL-based biotechnology company spun out of The Wertheim UF Scripps Institute (formerly Scripps Research, Florida). The company is focused on developing therapies for neuroscience and oncology indications using a platform that targets molecular nanomotor proteins. For more information, visit Contact: contact@ View original content to download multimedia: SOURCE Myosin Therapeutics Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
11 hours ago
- Yahoo
Global Mammography Equipment Market Accelerates with Smart Imaging Innovations
"AI-powered diagnostics, 3D imaging, and advanced techniques like CE DE Mammography and Molecular Breast Imaging are transforming breast cancer detection, driving demand for faster, safer, and more personalized screening solutions." BOSTON, Aug. 19, 2025 /PRNewswire/ -- According to the latest study from BCC Research, the "Global Mammography Equipment Markets" is projected to grow from $3.1 billion in 2025 to $4 billion by the end of 2030, at a compound annual growth rate (CAGR) of 5.2% from 2025 through 2030. This report provides a detailed review of the global mammography equipment market, highlighting current technologies, growth drivers, and emerging opportunities. The report segments by equipment type, end-user industry, and region. The analysis spans major global regions and countries, offering insights into market trends, ESG developments, patents, and technological innovations. It serves as a strategic resource for companies to understand procedural trends, brand perception, and competitive dynamics, helping them plan effectively and respond to potential market disruptions. The factors driving the market's growth include: Rising Global Incidence and Mortality of Breast Cancer: The growing number of breast cancer cases and related deaths worldwide is a major driver for mammography equipment. Early detection through screening is crucial for improving survival rates, which increases the demand for reliable and efficient diagnostic tools. Adoption of Mammography Screening: Due to heightened awareness, better healthcare access, and insurance coverage, more women are undergoing regular breast cancer screenings. This widespread adoption is fueling the need for advanced mammography systems in hospitals and clinics. Advances in AI Mammography and 3D Tomosynthesis: Innovations like 3D tomosynthesis and AI-enhanced imaging are making mammograms more accurate and efficient. These technologies help detect cancer earlier and reduce false positives, encouraging healthcare providers to upgrade their equipment. Development of Portable and Mobile Mammography Systems: To improve access in rural and underserved areas, manufacturers are creating portable and mobile mammography units. These systems support outreach programs and make screenings more accessible, expanding the market reach. Request a sample copy of the global market for mammography equipment report. Report Synopsis Report Metric Details Base year considered 2024 Forecast period considered 2025-2030 Base year market size $2.9 billion Market size forecast $4.0 billion Growth rate CAGR of 5.2% from 2025 to 2030 Segments covered Product Type and Sub-type, End User and Region Regions covered North America, Europe, Asia-Pacific, South America, and the Middle East and Africa (MEA) Countries covered The U.S., Canada, Mexico, Germany, the U.K., France, Italy, Spain, Rest of Europe, China, India, Japan, Australia, Rest of Asia-Pacific Market drivers • Rising global incidence and mortality of breast cancer. • Increased adoption of mammography screening. • Advances in imaging technology, including AI-powered mammography and 3D tomosynthesis. • Government Initiatives and awareness campaigns. • Development of portable and mobile mammography systems Interesting facts: According to GLOBOCON 2024, female breast cancer ranks second in terms of new cancer cases globally, with 2,308,897 new cases, accounting for 11.6% of all cancer diagnoses. It ranks fourth in cancer-related deaths, with 665,684 deaths, representing 6.9% of all cancer mortality. Several AI-powered mammography solutions, like iCAD's ProFound AI and Hologic's Genius AI Detection 2.0, have already received FDA approval. These systems don't just assist radiologists — they independently flag suspicious areas, helping to increase cancer detection rates and reduce reading time by up to 50%. Emerging startups: Therapixel: Therapixel, a France- and U.S.-based startup, gained significant momentum between 2021 and 2024 with its FDA-approved AI solution, MammoScreen. The software supports radiologists by scoring mammograms and highlighting suspicious areas, helping to detect breast cancer earlier while reducing reading time. Therapixel's advances have made AI-assisted screening more practical and reliable in busy clinical environments. Vara: Based in Germany, Vara expanded its AI platform from 2021 to 2024 into new regions such as Mexico and India. Vara's technology is integrated directly into breast cancer screening workflows, assisting radiologists by pre-analyzing mammograms and flagging cases for review. The report addresses the following questions: 1. What are the projected market size and growth rate? The global market for mammography equipment was $2.9 billion in 2024. The market is expected to grow at a compound annual growth rate (CAGR) of 5.2%, reaching about $4.0 billion by 2030. 2. Which factors are driving the growth of the market? Key market drivers include the following:- Increasing adoption of mammography screening.- Advances in imaging technology, including AI-powered mammography and 3D tomosynthesis.- Government Initiatives and awareness campaigns.- Increasing adoption of mammography screening.- Development of advanced therapeutics. 3. Which market segments are covered in the report? The market is segmented by product type, end-user, and region. The market is segmented by product into an analog mammography system, a digital mammography system, a portable and mobile mammography system, and others. The digital mammography system market is further segmented by full-field mammography system(FFDM), digital breast tomosynthesis system (DBT) and contrast-enhanced mammography system (CEM). End users include hospitals, surgical, diagnostic, and breast care centers. The regions covered include North America, Europe, Asia-Pacific, and the Rest of the World, focusing on major countries in these regions, including the U.S., Canada, Mexico, Germany, the U.K., Italy, France, Spain, and the Rest of Europe, China, Japan, India, South Korea, and the Rest of Asia-Pacific. 4. Which type segment will be dominant through 2030? Digital mammography systems will dominate the market through the end of 2030. 5. Which region has the highest market share? North America holds the highest share of the market. 6. What are the challenges and opportunities in the market? The mammography equipment market faces several key challenges, including concerns over radiation safety and a global shortage of radiologists. For example, according to a 2022 article by the Radiological Society of North America, the U.K. has only 8.5 radiologists per 100,000 people, well below the European average of 13 per 100,000. However, the market also presents strong opportunities. The development of portable and mobile mammography systems, increasing healthcare spending in emerging markets, and advances in imaging technologies, such as AI-powered mammography and 3D tomosynthesis, are expected to drive future growth and improve access to breast cancer screening worldwide. Market leaders include: BMI BIOMEDICAL INTERNATIONAL S.R.L. CANON INC. FUJIFILM HOLDINGS CORP. GE HEALTHCARE GENORAY CO. LTD. HOLOGIC INC. ITALRAY KONINKLIJKE PHILIPS N.V. METALTRONICA S.P.A. PLANMED OY SCREEN POINT MEDICAL BV SIEMENS HEALTHINEERS AG SHANGHAI UNITED IMAGING HEALTHCARE CO. LTD. STERNMED GMBH VILLA SISTEMI MEDICALI SPA Related reports: Nanotechnology in Cancer Treatment: Technologies and Global Markets: This report offers a comprehensive analysis of the nanotechnology market in cancer treatment, focusing on product types (like liposomes and dendrimers) and cancer types (such as lung and breast cancer). It covers global and regional trends, market drivers, restraints, opportunities, and competitive dynamics. The report aims to assess market potential, regulatory scenarios, and long-term impacts, providing detailed forecasts and market share insights for major players across major regions. Purchase a copy of the report direct from BCC Research. For further information on any of these reports or to make a purchase, contact info@ About BCC Research BCC Research market research reports provide objective, unbiased measurement and assessment of market opportunities. Our experienced industry analysts' goal is to help you make informed business decisions free of noise and hype. Contact Us Corporate HQ: 50 Milk St., Ste. 16, Boston, MA 02109, USA Email: info@ +1 781-489-7301 For media inquiries, email press@ or visit our media page for access to our market research library. Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. Logo: View original content to download multimedia: SOURCE BCC Research LLC Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13 hours ago
- Yahoo
TransCelerate and FDA Collaborate to Advance Use of Pragmatic Elements in Clinical Trials
New Summary Report and Resource Guide Highlight Opportunities to Integrate Research into Routine Care and Enable Broader Trial Participation PHILADELPHIA, Aug. 19, 2025 /PRNewswire/ -- TransCelerate BioPharma (TransCelerate), a nonprofit organization dedicated to improving the health of people around the world by accelerating and simplifying clinical research, today announced the release of a summary report from a tabletop exercise conducted with the U.S. Food and Drug Administration's (FDA) CDER Center for Clinical Trial Innovation (C3TI), along with the newly published resource, Getting Started with Embedded Pragmatic Trials: A Resource Guide. Held in December 2024, the exercise convened more than 30 pharmaceutical R&D leaders from TransCelerate member companies and eight FDA offices to identify actionable opportunities to scale the use of pragmatic elements in clinical trials to enable more research to be conducted at the point of care. Pragmatic trials offer simplified designs, leverage routine care settings, and reach broader, more representative patient populations—making them well-suited to address public health challenges and areas of significant unmet clinical need. "Collaborative efforts like this help surface practical considerations for embedding clinical research into routine care," said Rob DiCicco, Vice President of Portfolio Management at TransCelerate. "It also highlights the value of FDA's Streamlined Trials Embedded in clinical Practice (STEP) initiative in supporting innovative trial designs that can improve patient access and generate reliable evidence from real-world care settings." TransCelerate's Embedded Pragmatic Trials initiative aims to accelerate the adoption of these trial designs by building awareness, engaging in productive dialogue with regulatory authorities and other stakeholders, and offering practical tools to guide implementation. "Pragmatic trials have the potential to transform how clinical research is conducted – bringing trials closer to where care is delivered and expanding patient access to clinical trials," said Kevin Bugin, Head of Global Regulatory Policy at Amgen and executive sponsor of TransCelerate's Embedded Pragmatic Trials initiative. "This exercise represents a critical step toward enabling this vision, and we are grateful for the FDA's partnership and engagement." As part of the informal, non-binding exercise, TransCelerate presented a hypothetical case study evaluating a new indication for a post-approval medication. The clinical trial design incorporated several pragmatic elements, including simplified data collection, broad eligibility criteria, and integration with electronic health records (EHRs). Key themes from the session include: Design and Oversight Considerations: The value of hybrid trial designs, fit-for-purpose investigator and third-party oversight frameworks, and early feasibility assessments to ensure data readiness and regulatory alignment. Data Integrity and Endpoint Alignment: Opportunities to improve data quality by integrating EHR data with thoughtful quality-by-design (QbD) approaches and clarified endpoint definitions. Value of Broad Agency Collaboration: The need for aligned expectations regarding endpoint selection, adjudication, blinding and inspection priorities across multiple FDA offices. Operational Efficiency and Privacy: Exploration of computational methods to ensure data integrity while preserving patient privacy during inspections. In parallel with the tabletop exercise, TransCelerate has released Getting Started with Embedded Pragmatic Trials: A Resource Guide, a robust tool designed to build understanding of embedded pragmatic trials and provide practical guidance for successful implementation. The guide identifies resources to help stakeholders navigate the design and implementation of trials that incorporate pragmatic elements such as simplified data collection, broad eligibility criteria, and EHR integration. Looking Ahead TransCelerate will continue to collaborate with global regulators, sponsors, and stakeholders to: Advance understanding and adoption of pragmatic trials through real-world case studies, tools, and shared learnings. Clarify operational distinctions between pragmatic and traditional trial models. Identify infrastructure-ready geographies to support implementation at scale. The full report, Enabling the Implementation of Pragmatic Elements at Scale: Summary Report from an FDA and TransCelerate Tabletop Exercise, is available here: To learn more about TransCelerate's Embedded Pragmatic Trials Initiative, visit: About TransCelerate BioPharma BioPharma (TransCelerate) is a nonprofit organization that fosters collaboration across the global biopharmaceutical research and development community to simplify clinical trials and help bring new treatments to patients faster, safer, and more efficiently. Headquartered in the Philadelphia area, TransCelerate has 20 member companies and a robust portfolio of initiatives focused on transforming connectivity, enabling information sharing and reuse, and driving innovative trial designs. For more information, please visit View original content to download multimedia: SOURCE TransCelerate BioPharma
